Ascendia

  MARKET NEWS

Arvinas & Pfizer Announce Initial Phase 1b Data From the TACTIVE-U Sub-Study of Vepdegestrant in Combination With Abemaciclib
Ascendia Pharmaceutical Solutions Launched to Meet Drug Development & Manufacturing Needs
uniQure Announces Alignment With FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease
Zealand Pharma Announces First Participant Enrolled in Phase 2b Trial of Petrelintide in People With Overweight or Obesity
Eikonizo Therapeutics Announces Investment by Novo Nordisk; Advancing Lead Candidate Toward Clinical Development
Immutep Announces Initiation of Phase 3 Trial in First Line Non-Small Cell Lung Cancer
Scienture Announces Issuance of New Patent Covering its First Product Losartan Potassium Oral Suspension Through 2041
IMUNON Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 OVATION 2 Study of IMNN-001
NurExone Announces Promising Preclinical Results in Restoring Vision After Optic Nerve Damage
Bionical Emas Sells EMAS Pharma to Kester Capital Following Strategic Review

  EXPERT CONTENT & RESOURCES

CLINICAL TRIALS - Need for Accessibility to Meet FDA Guidance for Decentralized Trials

CLINICAL TRIALS - Need for Accessibility to Meet FDA Guidance for Decentralized Trials

Neil Vivian believes advances in electronic data collection and analysis are helping to make DCTs more accessible to broader and more diverse patient populations. Further innovations, particularly in artificial intelligence technology, are expected to accelerate these trends.  

DRUG-DEVICE DEVELOPMENT - Exploring the Complexities of Drug-Device Combination Products

DRUG-DEVICE DEVELOPMENT - Exploring the Complexities of Drug-Device Combination Products

Jeremy Guo, Senior Vice President at WuXi Biologics, and colleagues explain that many factors need to be taken into account when producing a Drug-Device Combination Product from development testing to fill/finish and assembly.

ALBA SUCCESS CASE

Container Selection for a Highly Sensitive Drug Product: A Success Story

For new drug products, it is essential that pharmaceutical companies utilize the experience of container suppliers as early as possible.

  FEATURED EDITORIAL

  COMPANY PROFILE

Woodstock Sterile Solutions is a global provider of best-in-class sterile development and manufacturing solutions – with a decades-long track record of helping healthcare companies advance molecules through clinical development into full-scale commercial production. Throughout our 50-year history, Woodstock has been a leader in developing and deploying advanced aseptic blow-fill-seal delivery products. We recently completed the expansion of our QC analytical laboratory, doubling the size of our previous space, and building on to our analytical expertise. We have enhanced our formulation and method development capabilities to offer fully integrated drug development and manufacturing services. Click here for more.

  WHITEPAPERS & WEBINARS

WEBINAR: Introducing Key Concepts in Tableting Research: Unleashing Essential Concepts and Strategies for Enhanced Formulation Development

WEBINAR: Introducing Key Concepts in Tableting Research: Unleashing Essential Concepts and Strategies for Enhanced Formulation Development

Tableting can present a series of challenges, particularly when dealing with formulations that have poor flowability, low compressibility, or high cohesivity. These issues can lead to manufacturing inefficiencies….

  WHITEPAPERS & WEBINARS

ARTICLE - A New Framework for Identifying Nitrosamine Risks & Efficiently Derisking Products

ARTICLE - A New Framework for Identifying Nitrosamine Risks & Efficiently Derisking Products

A clear standard for identifying APIs susceptible to Nitrosamine Drug Substance-Related Impurities (NDSRI) formation has been elusive—until now. Adare’s team of nitrosamine experts have developed a straightforward framework that simplifies the identification of at-risk APIs. Discover how this innovative approach …

WHITEPAPER - Concept to Commercialization: The Role of CDMOs in Driving Innovation Through Phase-Appropriate Technology Transfers

WHITEPAPER - Concept to Commercialization: The Role of CDMOs in Driving Innovation Through Phase-Appropriate Technology Transfers

CDMOs are emerging as critical drivers of innovation within the pharmaceutical and biotech industries. As the pharmaceutical industry continues to evolve, we can expect to see CDMOs play an increasingly important role in drug development and manufacturing. Many companies within …

WHITEPAPER - A Holistic Approach to Getting the First Batch Right

WHITEPAPER - A Holistic Approach to Getting the First Batch Right

By: Mark Rauckhorst, Director Supply Chain and Project Management, Vetter Development Service USA. Inc.

Clinical trials are high-visibility milestones for investors, as this is often the first major step toward financial return on what has likely been years of investment …

CASE STUDY - Overcoming Barriers to Patient Adherence With A Novel Dosage Form

CASE STUDY - Overcoming Barriers to Patient Adherence With A Novel Dosage Form

When a mid-sized pharmaceutical company asked Adare to make a version of their drug that was more convenient for patients with tremors or swallowing difficulties, our experts created a sprinkle formulation of the drug. In this CPHI Award-winning case study, …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

December 18 – Lyophilization Manufacturing
January 8 – Capsules